ClinicalTrials.gg
RecruitingNCT07212465NACC-DUpdated Oct 28, 2025

Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression

An interventional study of Active Brainsway H7-Coil Deep TMS System and Sham Brainsway H1-Coil Deep TMS System in Major Depressive Disorder (MDD), sponsored by Rotman Research Institute at Baycrest. Recruiting at 1 site in Canada. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Rotman Research Institute at Baycrest · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 312 studies in Depressive Disorder, Major with a site in Canada — 66 open to participants now, 82 under way, 12 of them phase 3. Depressive Disorder, Major · Canada.

Planned enrollment
217th of 284
24 · median 70
Started
2025
with 18 others
No phase
132 of 312
36 open now
Primary completion
2027-01
later than 36 of 81 live
Registered
296th of 312
by date

Among the 312 studies in Depressive Disorder, Major with a site in Canada, this one is the 217th largest by planned enrollment of the 284 interventional ones that give a count, is one of 19 that started in 2025, is one of 132 with no phase, reaches primary completion later than 36 of the 81 other live ones, and was the 296th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

66 of the 312 studies in Depressive Disorder, Major with a site in Canada are open now. Recruiting first, the newest first:

60 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Depressive Disorder, Major with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have not tolerated or responded to antidepressant medications. The study will evaluate whether accelerated dTMS administered over 5 consecutive days is safe and well-tolerated in this population, and whether it produces greater reductions in depressive symptoms compared to placebo stimulation.

Read the detailed description

This study will investigate the effects of an accelerated intermittent theta burst protocol (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to target the anterior cingulate cortex (ACC) in older adults (aged 60-85) with Major Depressive Disorder (MDD). Twenty-four older adults with treatment-resistant MDD will participate in a single site, double-blind, randomized sham-controlled trial using an accelerated schedule of multiple dTMS sessions per day for 5 consecutive days. The primary goal of the study is to establish the feasibility of an accelerated aiTBS protocol of the ACC in older adults with treatment resistant depression, and to obtain preliminary evidence of treatment efficacy.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Transcranial Magnetic Stimulation (TMS)
  • Treatment Resistant Depression
  • Intermittent Theta Burst Stimulation
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are between 60- 85 years old (on the day of randomization)
  • have been diagnosed with DSM5 Major Depressive Disorder, with the current episode longer than 4 weeks but less than 5 years
  • did not respond to/did not tolerate, or failed to achieve remission with at least one antidepressant trial of 8 week minimum duration
  • are willing to provide
  • are able to follow the treatment schedule
  • are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)
  • have a satisfactory safety screening questionnaire for TMS

Exclusion criteria

Exclusion Criteria:

  • have a metal plate in your head (such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe
  • have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures
  • have a cardiac pacemaker
  • have an implanted medication pump
  • have a central venous line
  • have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia
  • have a history of substance abuse in the last 6 months
  • have a history of stroke or other brain lesions
  • have a personal history of epilepsy
  • have a family history of epilepsy
  • are a pregnant or breast-feeding woman
  • have a history of abnormal MRI of the brain
  • have untreated hypo- or hyper-thyroidism
  • have unstable medical condition(s)
  • have any other known to TMS
  • are on unstable doses of any psychotropic medication such as - antidepressants, antipsychotic, mood stabilizers or memory enhancing medications
  • require daily doses of benzodiazepines or hypnotics within two weeks of randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Sham comparator
    20-40 sessions of sham stimulation

    Participants will receive sham intervention if randomized into sham condition. The sham intervention consists of treatment with similar technical parameters which induce scalp sensations but do not penetrate into the brain.

    Device: Sham Brainsway H1-Coil Deep TMS System

  • Experimental
    20-40 sessions of iTBS dTMS

    Participants will receive dTMS if randomized into the active condition. The motor threshold (MT) will be measured by delivering single stimulations to the motor cortex with gradually increased intensity. The stimulation protocol consists of 6-8 dTMS sessions of intermittent theta burst stimulation delivered at an intensity of 80-90% of resting MT each day for five consecutive days

    Device: Active Brainsway H7-Coil Deep TMS System

Interventions

  • DeviceActive Brainsway H7-Coil Deep TMS System

    Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.

  • DeviceSham Brainsway H1-Coil Deep TMS System

    In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Percentage of scheduled treatment sessions that are attended by study participants

    Time frame: 6 weeks

  2. Participant-reported comfort and feasibility based on the frequency and type of adverse events as measured using the Adverse Events Questionnaire (AEQ)

    Severity of symptoms is rated from 1 to 4, with 1 being absent and 4 being severe. Whether symptoms are perceived to be relatedTMS treatment are rated from 1 to 5, with 1 being no and 5 being definitely.

    Time frame: 6 weeks

  3. The number of participants who have prematurely withdraw and reasons for withdrawal

    Time frame: 6 weeks

  4. The change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores following the final treatment on day 5 (i.e., after 5 days of H7-coil a-iTBS) in the treatment group compared to the sham group.

    An effect size (Cohen's d) of 0.5 will be considered a minimally important effective size. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms.

    Time frame: 1 week

Secondary outcomes

  1. Response rates compared between treatment groups following 5 days of treatment, where the response rate refers to the percentage of patients who responded to a-ITBS treatment and response is defined as a ≥50% reduction in MADRS score from baseline

    Response rates will be compared from baseline to after 5 day treatment and at 1 month follow-up. MADRS scores range from 0-60, with a greater score indicating greater severity of depressive symptoms.

    Time frame: 6 weeks

  2. Remission rates compared between treatment groups following 5 days of treatment, where the remission rate is defined as MADRS score <10

    MADRS scores will be compared between baseline, after 5 days of treatment and at 1-month follow-up. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms

    Time frame: 6 weeks

  3. The change in baseline slow wave and resting state activity as measured with electroencephalography (EEG) following 5 days of treatment and at 1-month follow-up

    Time frame: 6 weeks

  4. The change in functional connectivity within the default mode and central autonomic networks on Magnetic Resonance Imaging (MRI)

    Time frame: 1 week

  5. The change in slow wave activity in the posterior default mode network (posterior cingulate cortex) as measured with MEG

    Time frame: 1 week

  6. The change in baseline cognitive tests following 5 days of treatment and at 1-month follow-up (cognitive domains tested include executive function and memory),

    Baseline cognitive tests will be measured using a neuropsychological test battery.

    Time frame: 6 weeks

  7. The change in baseline resting state heart rate variability (HRV) following a single TMS session and after 5 days of treatment

    Time frame: 1 week

  8. The change in baseline emotional processing as measured with an Affective Simon task following a single TMS session, after 5 days of treatment and at 1-month follow-up

    The Affective Simon task will measure the number of correct responses to stimuli in the task.

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 17 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Oct 8, 2025
StartActual
Jul 21, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 15, 2027
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07212465
Lead sponsor
Rotman Research Institute at Baycrest
Responsible party
Linda Mah, MD (Clinician Scientist, Rotman Research Institute at Baycrest) — Principal investigator
First posted
Oct 8, 2025
Start date
Jul 21, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Oct 28, 2025

Study contacts

Amanda Chao, MPH
Contact
preventad@research.baycrest.org
416-785-2500 ext. 3434
Linda Mah, MD
Contact
preventad@research.baycrest.org
416-785-2500 ext. 3434
Linda Mah, MD
principal investigator · Baycrest Rotman Research Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion